Home | Welcome to Contract Pharma   
Last Updated Saturday, May 18 2013
Print RSS Feed

Breaking News

Related Searches: Promotions & Moves •
Avéma Pharma Solutions

January 6, 2009
Thomas M. Salus has been appointed vice president, contract services, Avéma Pharma Solutions, a division of PL Developments, and Richard Thome has been named senior vice president, operations of both PL Developments and Avéma Pharma Sol…  Read More »
Galapagos Earns GSK Milestones

January 6, 2009
Galapagos NV has successfully achieved a pre-clinical candidate drug in its osteoarthritis alliance with GlaxoSmithKline. Galapagos also reached milestones on other compounds in the alliance, earning milestone payments totaling $10.5 million. Under t…  Read More »
Valeant Pharmaceuticals

January 6, 2009
Rajiv De Silva has been appointed chief operating officer of Specialty Pharmaceuticals, Valeant Pharmaceuticals International, effective January 5, 2009. Mr. De Silva will be responsible for overseeing the U.S., Canadian and Australian specialty phar…  Read More »
PPD, Merck Enter Vax-Lab Pact

January 5, 2009
PPD, Inc. has purchased Merck’s 130,000-sq.-ft. vaccine testing lab and related equipment in Wayne, PA and hired the 80 Merck employees who operate the facility. PPD will provide assay development and immunogenicity testing services to support…  Read More »
DOR Gets SPA Clearance for orBec Trial

January 5, 2009
DOR BioPharma, Inc. has reached agreement with the FDA on the design of a confirmatory Phase III trial for its lead product orBec for the treatment of acute gastrointestinal Graft-versus-Host Disease (GI GVHD). The agreement was made under the FDA's…  Read More »
Xoma, Ltd.

January 5, 2009
Fred Kurland has been appointed vice president, finance and chief financial officer at Xoma, Ltd. Mr. Kurland will be responsible for directing the company's financial strategy, accounting, financial planning and investor relations functions.  …  Read More »
Nektar Sells Pulmonary Delivery Assets to Novartis

December 31, 2008
Nektar Therapeutics has sold some of its pulmonary delivery assets, technology, and intellectual property to Novartis for $115 million in cash. Novartis now owns "certain dry powder and liquid pulmonary formulation and manufacturing assets, incl…  Read More »
Hovione

December 30, 2008
Roger Viney, Ph.D. has been named director of sales & marketing Europe and Asia for Hovione. Thomas Eisele, Ph.D. has been named general manager R&D at the company and Steve Beagle has been named director of sales & marketing, North Ameri…  Read More »
King Starts Phase II for Pain Drug

December 30, 2008
King Pharmaceuticals has initiated the Phase II trial evaluating the efficacy and safety of T-62, an investigational drug for the treatment of neuropathic pain. Dr. Eric Carter, chief science officer of King, remarked, “T-62, a new chemical…  Read More »
Onyx Pharmaceuticals

December 30, 2008
Matthew K. Fust has been named executive vice president and chief financial officer of Onyx Pharmaceuticals. Mr. Fust will serve as Onyx's principal financial and accounting officer and report to N. Anthony Coles, M.D., the company's president and ch…  Read More »
Actavis Reaches Consent Degree Over NJ Facilities

December 30, 2008
Actavis Inc. has reached agreement with the FDA on a Consent Decree of Permanent Injunction the company’s Actavis Totowa LLC subsidiary. This agreement, in effect, settles the issues identified by the Department of Justice in its previously fil…  Read More »
Savient BLA Gets Priority Review

December 30, 2008
The FDA has accepted Savient Pharmaceuticals' BLA for pegloticase, a novel biological drug for treatment-failure gout (TFG) patients. The FDA also granted Savient's BLA a priority review status which accelerates the review period to six months. This…  Read More »
GSK, Archemix Form Strategic Aptamers Alliance

December 23, 2008
GlaxoSmithKline and Archemix Corp. have entered a worldwide strategic alliance to discover, develop and commercialize aptamer therapeutics to treat inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. Aptamers are synth…  Read More »
Pierre Fabre, Forest Labs Enter Depression Drug Pact

December 23, 2008
Forest Laboratories, Inc. and Pierre Fabre Medicament have entered into a definitive collaboration agreement to develop and commercialize F2695 in the U.S. and Canada. F2695 is a selective norepinephrine and serotonin reuptake inhibitor being develop…  Read More »
Kendle

December 23, 2008
Kerri Schoedel, Ph.D. has been promoted to scientific director, clinical pharmacology for Kendle's Early Stage unit in Toronto. Dr. Schoedel will provide overall scientific direction and leadership to the clinical pharmacology group, as well as lead…  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: